Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
11,381 total articles
We upgrade Netflix to Buy and propose an aggressive long ahead of the next earnings print. Netflix combines strong operating margins, meaningful free cash flow ($9.46B trailing), and a growing ad business that management expects to double in 2026. At $95.32 the risk/reward favors a long exposure into earnings and the post-earnings reaction, but thi…
Meta is trading at roughly $1.47T with $46.1B in free cash flow and a PE of ~24. Management's AI product stack — from ad targeting to developer APIs and AR experiences — has near-term revenue vectors that the market is underpricing. I outline a long trade with entry, stop and target plus catalysts and risks.
Coca-Cola HBC looks set to benefit materially from a large acquisition in Africa that should expand market share, improve unit economics and lift margins. With clear operational levers and visible synergy potential, the stock offers an asymmetric risk-reward for a mid-term (45 trading days) swing trade. Entry $40.00, target $48.00, stop $36.00.
Microsoft's share price has retreated from 52-week highs while fundamentals remain robust: $2.76T market cap, $77B in free cash flow and a 30% return on equity. For value-minded investors who believe AI adoption sustains enterprise spending, MSFT is an actionable long with a clear entry, stop and upside target over the next 180 trading days.
Perpetua Resources (PPTA) is sitting at the center of two market themes - U.S. critical minerals security and renewed interest in antimony as a strategic byproduct. With the Stibnite Gold Project advancing and government capital flowing to domestic supply chains, I see a tradable upside to $36.00 from an entry at $29.00 over a mid-term horizon, whi…
Constellation Brands (STZ) looks like an actionable long after a difficult 2025 and early-2026 pullback. The business still generates strong free cash flow ($1.76B), carries a $26B market cap and a 2.95% yield, and is trading near $149. This trade targets a recovery back toward Street estimates and prior analyst targets while protecting capital wit…
IBM has pulled back from its 52-week high and is trading below several moving averages, but fundamentals remain intact: $12.1B free cash flow, a $228B market cap, and a P/E near 21.5x. Technicals show room to rebound (RSI ~44, positive MACD histogram) and strategic partnerships — including a recent security tie-up with CrowdStrike and Intel — reinf…
Marvell just secured a transformational strategic partnership with Nvidia that pairs Marvell's networking, custom processors and silicon-photonics strengths with Nvidia's AI compute scale. With data-center revenue growing 21% year-over-year and management guiding to ~40% in fiscal 2027, Marvell's growth trajectory and reasonable cash generation arg…
J.Jill (JILL) has been punished to near-term lows after weak top-line trends and margin pressure. At roughly $11.56, the shares trade below $12 with a market cap near $175M, earnings of about $2.26 per share and compelling cash flow metrics. The combination of a low P/E (~5-6), EV/EBITDA ~2.36, a dividend yield near 2.8%, and a heavily oversold tec…
Upstart is back to bargain territory: market cap around $2.5B, profitable on an EPS basis, and trading nearer its 52-week low despite solid growth and improving momentum. This trade targets a mean reversion plus re-rating over the next 45 trading days with a strict stop under the recent low.
POW (VistaShares Electrification Supercycle ETF) offers cheap, focused exposure to companies tied to the electrification value chain at $24.20. Technicals and short activity suggest a tactical re-acceleration is possible toward the 52-week high near $26.68, but macro reinflation and rotation into value could quickly compress multiples. This trade r…
Sony Group trades at $21.26 with a $127.9B market cap and a modest 2.37x book multiple after a year of sector pressure. Trailing earnings are negative, but a forward EPS of roughly $1.42 would put the stock at 15x and is well within reach if PlayStation pricing, content monetization, and imaging-semiconductor recovery normalize. We upgrade to Buy w…
adidas (ADDYY) shows signs of operational stabilization: a reasonable P/E of 18, falling short interest, improving technical momentum, and a market cap of about $28.9B that does not fully reflect the recovery in fundamentals. We upgrade to a tactical long with entry at $80.19, a stop at $76.00, and a primary target of $95.00 over a position horizon…
Nordic American Tankers (NAT) offers a compelling risk-reward for long-term investors: expanding Suezmax fleet, a recently raised dividend (30%), insider buying, and a lean float with occasional heavy short interest. Enter at $5.88, hold through 180 trading days, target $8.00 with a $4.60 stop.
Nvidia's leadership in AI datacenter GPUs, massive free cash flow and improving adoption tailwinds make the case for a multi-trillion-dollar revaluation. This trade idea outlines a long-term long position with a $400 target over ~180 trading days, a clear stop, and the catalysts and risks that could push shares toward a higher valuation.
Alcoa (AA) is benefiting from a global aluminum supply squeeze, attractive earnings and cash-flow metrics, and a modestly valued enterprise. I recommend a long trade with a $68.00 entry, $82.00 target and $60.00 stop, sized for a medium-risk portfolio and held over the next 180 trading days while catalysts play out.
Insmed's market cap sits around $35 billion while revenue expectations are still ramping. Recent FDA approval of BRINSUPRI and an advancing inhaled treprostinil program mean the company is finally building commercial scale. This trade idea bets the pipeline execution and near-term catalysts will push the stock higher, while recognizing the balance …
Vista Energy (VIST) has turned operational strength in Vaca Muerta into improving cashflow and investor interest. With a market cap near $7.2B, high profitability in recent quarters, and rising technical momentum, VIST looks like a constructive mid-term long. This trade idea lays out an entry at $75.53, a stop at $68.00 and a target at $92.00 over …
Amentum's recent contract wins and the Torus defence supply chain alliance reinforce our thesis that the company’s backlog and services focus will support revenue visibility into 2027. The stock is recovering from oversold territory but still trades below recent highs; we outline a long trade with defined entry, targets, and stop loss tied to contr…
LENZ Therapeutics is a pre-commercial eye-care biotech trading at a $286M market cap after a rocky launch quarter and a recent earnings miss. The company’s lead candidate, LNZ100, has strong Phase 3 data and prescription momentum signals (VIZZ scripts), while fundamentals show a stretched cash profile and heavy shorts. This is a speculative, high-r…
Lonza (LZAGF) looks like an actionable long after a period of weakness. Corporate refocus following the CHI exit reduces distraction and should improve execution on higher-margin lines. Technicals show bullish momentum (MACD histogram positive, price holding above 10/20-day averages) while the 50-day still offers upside near-term. Elevated short in…
Micron is getting punished on fears that compression algorithms and aggressive capex will cap memory pricing. The fundamentals and cash-flow profile argue the pullback is an overreaction. This trade buys a disciplined dip: enter $340.00, stop $305.00, target $460.00 over a 180-trading-day horizon.
Adeia (ADEA) is a small-cap technology licensor whose hybrid bonding and 3D integration patents are finding renewed commercial traction. Recent multi-year renewals, a new agreement with UMC, improving free cash flow and an expanding addressable market for chiplet architectures create a path for upside. This trade idea lays out an actionable entry, …
Credo Technology is a core AI-infrastructure supplier showing explosive revenue growth and industry-leading gross margins, but the stock has been punished by momentum and sentiment despite healthy cash flow and a clean balance sheet. This trade idea lays out a size-up plan with entry, stop, and target prices across time horizons while highlighting …
Boston Scientific (BSX) has moved from a hypergrowth narrative centered on electrophysiology into a more diversified, cash-generative company. A sell-off after trial readouts and guidance misses created a buying opportunity at about $63. This trade idea frames a long position aimed at riding valuation re-rating and durable compounding over the next…
